This revolutionary new ADHD treatment costs $1,000
For the first time, the Food and Drug Administration has approved a treatment for ADHD that isn't a drug. Instead, it's a medical device, known as Monarch eTNS, that works by stimulating the nervous system with an electric current.
Nervous stimulation at different parts of the body has been proven effective in treating conditions like depression and epilepsy, CBS New York explained. The device administers a mild "electrical shock" — in ADHD cases, to the nerves in the forehead — which is thought to help calm the part of the brain that causes the hyperactivity typical of people with ADHD.
This treatment is groundbreaking because ADHD treatment is tricky. While several drugs have proven effective, they often come with side effects. On the other hand, going without treatment can often lead to further mental health complications, such as "depression, chemical dependency, trouble learning in school, and trouble with the law," said Jeffrey Borenstein, the CEO of the Brain & Behavior Research Foundation.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
So non-drug treatments like this one are a major step in reducing the side effects and complications in people with ADHD. While it's still not entirely clear why electrical stimulation helps with hyperactivity, double-blind studies have found significant success, which is why the FDA approved the Monarch eTNS for treatment.
Further studies will need to be conducted to answer questions of how long the effects last, whether the Monarch eTNS can entirely replace ADHD drugs, and whether this will work with people of different ages. But for now, the device is available by prescription for about $1,000. Read more at CBS New York.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Shivani is the editorial assistant at TheWeek.com and has previously written for StreetEasy and Mic.com. A graduate of the physics and journalism departments at NYU, Shivani currently lives in Brooklyn and spends free time cooking, watching TV, and taking too many selfies.
-
Why Britain is struggling to stop the ransomware cyberattacksThe Explainer New business models have greatly lowered barriers to entry for criminal hackers
-
Greene’s rebellion: a Maga hardliner turns against TrumpIn the Spotlight The Georgia congresswoman’s independent streak has ‘not gone unnoticed’ by the president
-
Crossword: October 26, 2025The Week's daily crossword puzzle
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials